Jackie Fouse, Agios

Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

Agios made its name as a can­cer drug de­vel­op­er un­der the leg­endary founder David Schenkein, who took the com­pa­ny from a fa­mous­ly blank sheet of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.